Not medical advice. This website is not medical advice, a diagnosis, a match to a trial, or a recommendation to join a study. Listings are plain-English rewrites of public ClinicalTrials.gov records. Whether a site is still enrolling, and whether you qualify, can only be confirmed by the study team and your clinician. Source registry: ClinicalTrials.gov. Editorial rules: methodology.
PlainTrials
RecruitingPhase 4interventionalRules rewrite

Phase 4: testing Rimegepant 75 mg ODT for Acute Treatment of Migraine

This is a multicenter, single-arm, open-label Phase 4 study evaluating the whether it is safe and how hard side effects are to live with of rimegepant 75 mg orally disintegrating tablet (ODT) for the acute treatment of migraine (with or without aura) in adult patients in India who have had an insufficient response, intolerance, or contraindication to triptans. It will enroll approximately 60 participants.

Official registry: https://clinicaltrials.gov/study/NCT07685769 · Pfizer · enrollment listed as 60

What this phase means

Phase 4: the treatment is already approved. This study asks new questions — longer-term effects, other diseases, or how it compares in everyday care.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

If you join, the listed intervention(s) are Rimegepant 75 mg ODT. The registry lists allocation as na. This is a multicenter, single-arm, open-label Phase 4 study evaluating the whether it is safe and how hard side effects are to live with of rimegepant 75 mg orally disintegrating tablet (ODT) for the acute treatment of migraine (with or without aura) in adult patients in India who have had an insufficient response, intolerance, or contraindication to triptans.

They plan to enroll about 60 people at 7 sites. Taking part typically means taking a study drug (or dummy pill) plus check-ins.

Official title (unrewritten)

AN OPEN-LABEL MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF RIMEGEPANT 75 MG ODT FOR ACUTE TREATMENT OF MIGRAINE IN ADULT PARTICIPANTS IN INDIA WITH PREVIOUS INSUFFICIENT RESPONSE TO TRIPTANS

Interventions: Rimegepant 75 mg ODT

Primary outcome (registry wording): Incidence of Treatment-emergent adverse events (TEAEs)

Who it is for (from inclusion criteria)

  • Ages 18 Years to any
  • Participants are eligible to be included in this study only if all of the following criteria apply:
  • Age and Reproductive Status:
  • 18 years of age or older who meet the reproductive criteria
  • Disease Characteristics:
  • Participant has at least a 1-year history of migraine (with or without aura) consistent with a diagnosis according to the International Classification of Headache Disorders, 3rd Edition, including the following:
  • At least 5 attacks fulfilling criteria 1-3:
  • Headache attacks lasting 4-72 hours (when untreated or unsuccessfully treated)

Public study contact (from the registry)

Pfizer CT.gov Call Center

1-800-718-1021

ClinicalTrials.gov_Inquiries@pfizer.com

Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.

Sites listed on ClinicalTrials.gov

7 listed

Related recruiting trials in this snapshot

FAQ about this NCT record

Is NCT07685769 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT07685769?

Phase 4. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT07685769?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary